Quantcast
Latest Stories

Controlling blood sugar the natural way



Diabetes care pioneer Novo Nordisk has developed a novel type of medicine for type 2 diabetes that controls blood sugar the natural way.

“Liraglutide mimics the action of a hormone released from the small intestine after food intake. This hormone, a type of incretin called GLP-1, helps the pancreas control blood sugar more efficiently,” said Diabetes Research Division head Dr. Filip K. Knop of the  Gentofte Hospital, University of Copenhagen, Denmark.

“Liraglutide signals the pancreas to secrete more insulin to help lower blood sugar quickly. At the same time, it suppresses the pancreas from secreting too much glucagon, a hormone that releases glucose from the liver and raises blood sugar levels,” said Makati Medical Center consultant endocrinologist Dr. Augusto D. Litonjua.

The two experts spoke during a lunch symposium organized by Novo Nordisk on March 20, at the Edsa Shangri-La Hotel in Mandaluyong City. Around 200 local internists, cardiologists and endocrinologists attended the symposium.

Liraglutide belongs to a class of diabetes medicines called GLP-1 receptor agonists. Also called incretin mimetics, GLP-1 receptor agonists mimic the action of intestinal GLP-1. While the effects of GLP-1 only last for a few minutes, the half-life of liraglutide is about 10-13 hours.

Liraglutide is 97 percent similar to GLP-1. By acting like GLP-1, liraglutide helps make more insulin available in the bloodstream to help lower blood sugar levels quickly. Liraglutide triggers important cells in the pancreas, called beta cells, to make insulin when blood sugar is high. This is important because, over time, beta cells stop working in people with type 2 diabetes. By the time of diagnosis, about 50 percent of beta cells are no longer working the way they should. Liraglutide helps beta cells work the way they should.

Unique mechanism of action

“Unlike other anti-diabetes medications [e.g. sulphonylureas] that stimulate insulin secretion all the time, liraglutide stimulates insulin secretion only when there is a need for it—after a meal when blood sugar levels are high,” said Dr. Knop. “Because of its unique mechanism of action, liraglutide does not cause hypoglycemia [low blood sugar], a dangerous condition associated with certain anti-diabetes medications.”

“GLP-1 receptor agonists such as liraglutide provide multiple benefits to patients with type 2 diabetes,” said Dr. Litonjua. These include normalizing after-meal (postprandial) blood sugar levels, suppressing inappropriately high glucagon secretion, improving beta cell responsiveness and nighttime insulin secretion, decreasing appetite and weight, and significantly lowering HbA1c, a key measure of diabetes control.

Liraglutide is a once-a-day injectable medication indicated for the treatment of type 2 diabetes when diet and exercise alone are not enough to control blood sugar levels. It can be used together with other diabetes medications, such as metformin, sulfonylureas [e.g. glimepiride or glicazide] and pioglitazone. Liraglutide comes in a prefilled pen that is injected at any time of the day under the skin of the stomach, thigh, or upper arm. Philippine Daily Inquirer


Follow Us


Follow us on Facebook Follow on Twitter Follow on Twitter


Recent Stories:

Complete stories on our Digital Edition newsstand for tablets, netbooks and mobile phones; 14-issue free trial. About to step out? Get breaking alerts on your mobile.phone. Text ON INQ BREAKING to 4467, for Globe, Smart and Sun subscribers in the Philippines.

Tags: blood sugar , diabetes , Health

  • http://www.facebook.com/bobbydecastro Bienvenido G. de Castro

    Endocrinologists should take note of this medical discovery. It is a good development.



Copyright © 2014, .
To subscribe to the Philippine Daily Inquirer newspaper in the Philippines, call +63 2 896-6000 for Metro Manila and Metro Cebu or email your subscription request here.
Factual errors? Contact the Philippine Daily Inquirer's day desk. Believe this article violates journalistic ethics? Contact the Inquirer's Reader's Advocate. Or write The Readers' Advocate:
c/o Philippine Daily Inquirer Chino Roces Avenue corner Yague and Mascardo Streets, Makati City, Metro Manila, Philippines Or fax nos. +63 2 8974793 to 94
Advertisement
Advertisement

News

  • Seabed search for missing Malaysian jet to widen
  • Lacson rejects calls to name ‘pork’ execs
  • Obama due in Seoul as North Korea nuclear test fears grow
  • Hold departure order out vs Corona, Singson
  • Malaysia to release MH370 report–PM
  • Sports

  • Michael Phelps loses to Lochte in comeback meet
  • Sharapova advances to Stuttgart quarterfinals
  • Galedo caps ride of redemption
  • Beermen, Express dispute second semis slot today
  • Lady Agilas upset Lady Bulldogs in four sets
  • Lifestyle

  • ‘Recovered’ Banksy works on display ahead of sale
  • Marinduque: Visiting the ‘palm of the ocean’
  • First at Vatican in 60 years
  • How Jing Monis Salon gave Krissy the pixie
  • Want to be a supermodel? Work on your inner beauty, says Joey Espino
  • Entertainment

  • Paul McCartney to play at Candlestick concert
  • Kristoffer Martin: from thug to gay teen
  • Has Ai Ai fallen deeply with ‘sireno?’
  • California court won’t review Jackson doctor case
  • Cris Villonco on play adapted from different medium
  • Business

  • PAL hailed for ban on shark fin cargo
  • BSP to change tint of P100 bill
  • Nielsen sees car buying boom in the Philippines
  • How author of best-seller exposed ‘one percent’ economic elite
  • Bangko Sentral readies new bank lending rules
  • Technology

  • Cloud strength helps Microsoft earnings top Street
  • Vatican announces hashtag for April 27 canonizations
  • Enrile in Masters of the Universe, Lord of the Rings?
  • Top Traits of Digital Marketers
  • No truth to viral no-visa ‘chronicles’
  • Opinion

  • Corruption not invincible after all
  • Editorial Cartoon, April 25, 2014
  • No deal, Janet
  • Like making Al Capone a witness vs his gang
  • MERS-CoV and mothers
  • Global Nation

  • Filipinos second-shortest in Southeast Asia
  • China welcomes PH apology
  • Only 4 Etihad passengers not accounted for
  • Abandoned in Malta,15 PH seamen return
  • Senator hopes PH will also get same vow
  • Marketplace